BRPI0812875A2 - " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ". - Google Patents

" método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ".

Info

Publication number
BRPI0812875A2
BRPI0812875A2 BRPI0812875-8A2A BRPI0812875A BRPI0812875A2 BR PI0812875 A2 BRPI0812875 A2 BR PI0812875A2 BR PI0812875 A BRPI0812875 A BR PI0812875A BR PI0812875 A2 BRPI0812875 A2 BR PI0812875A2
Authority
BR
Brazil
Prior art keywords
individual
risk
severa
heparin
sep
Prior art date
Application number
BRPI0812875-8A2A
Other languages
English (en)
Inventor
Lars Bjoerck
Bertil Christensson
Heiko Herwald
Adam Linder
Per Aekesson
Original Assignee
Hansa Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38331957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0812875(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hansa Medical Ab filed Critical Hansa Medical Ab
Publication of BRPI0812875A2 publication Critical patent/BRPI0812875A2/pt
Publication of BRPI0812875B1 publication Critical patent/BRPI0812875B1/pt
Publication of BRPI0812875B8 publication Critical patent/BRPI0812875B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0812875A 2007-06-12 2008-06-12 " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste BRPI0812875B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0711327.7 2007-06-12
GBGB0711327.7A GB0711327D0 (en) 2007-06-12 2007-06-12 Diagnostic method
PCT/EP2008/004743 WO2008151808A1 (en) 2007-06-12 2008-06-12 Diagnostic method

Publications (3)

Publication Number Publication Date
BRPI0812875A2 true BRPI0812875A2 (pt) 2014-12-09
BRPI0812875B1 BRPI0812875B1 (pt) 2017-12-05
BRPI0812875B8 BRPI0812875B8 (pt) 2022-07-12

Family

ID=38331957

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812875A BRPI0812875B8 (pt) 2007-06-12 2008-06-12 " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste

Country Status (16)

Country Link
US (3) US8518648B2 (pt)
EP (1) EP2129391B1 (pt)
JP (1) JP5166522B2 (pt)
KR (1) KR101563997B1 (pt)
CN (2) CN103543271A (pt)
AT (1) ATE548050T1 (pt)
AU (1) AU2008261252B2 (pt)
BR (1) BRPI0812875B8 (pt)
CA (1) CA2690067C (pt)
DK (1) DK2129391T3 (pt)
ES (1) ES2380875T3 (pt)
GB (1) GB0711327D0 (pt)
PL (1) PL2129391T3 (pt)
PT (1) PT2129391E (pt)
SI (1) SI2129391T1 (pt)
WO (1) WO2008151808A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
JP5488885B2 (ja) * 2009-10-28 2014-05-14 国立大学法人 東京大学 感染症の疾患マーカー
GB201016161D0 (en) * 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
AU2011334548B2 (en) * 2010-11-26 2016-06-09 Immunexpress Pty Ltd Diagnostic and/or screening agents and uses therefor
GB201102108D0 (en) * 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
AU2012308365A1 (en) * 2011-09-16 2014-04-24 Cepheid Methods of detecting sepsis
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
US10761093B2 (en) 2014-10-09 2020-09-01 Texas Tech University System Microdevice for cell separation utilizing activation phenotype
CN109541235A (zh) * 2018-08-19 2019-03-29 重庆早柒天生物科技股份有限公司 肝素结合蛋白和降钙素原二联检测试剂盒及其制备方法
US20220178932A1 (en) 2019-04-24 2022-06-09 Japanese Foundation For Cancer Research Cancer detection method and detection reagent
CN111208305B (zh) * 2020-02-16 2023-04-25 重庆翼锋生物科技有限公司 Hbp和pct在败血症诊断试剂制备中的用途
CN111951963B (zh) 2020-07-30 2022-09-02 中翰盛泰生物技术股份有限公司 Hbp在covid-19患者的预后风险预警中的应用
US20240230674A1 (en) * 2021-04-30 2024-07-11 Roche Diagnostics Operations, Inc. Strem1 marker panels for early detection of sepsis
JP2024516680A (ja) * 2021-04-30 2024-04-16 エフ． ホフマン－ラ ロシュ アーゲー 敗血症の早期検出用のｉｌ６マーカーパネル
EP4330685A2 (en) * 2021-04-30 2024-03-06 Roche Diagnostics GmbH Ngal marker panels for early detection of sepsis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627262A (en) 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
US5962241A (en) * 1989-07-28 1999-10-05 The University Of Arizona Monoclonal antibody detection of proteins on sperm related to fertility
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
HU221638B1 (hu) 1994-04-21 2002-12-28 Leukotech A/S Heparinkötő fehérje alkalmazása szepszis kezelésére szolgáló gyógyszer előállítására
US5976536A (en) 1995-08-09 1999-11-02 Emory University Neisseria mutants, lipooligosaccharides and immunogenic compositions
US5778895A (en) 1997-01-29 1998-07-14 Uab Research Foundation Method of discriminating bacterial from aseptic meningitis
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7655480B2 (en) 2002-03-08 2010-02-02 The Board Of Regents Of The University Of Oklahoma Method for predicting sepsis or an acute infectious inflammatory response
AU2003220034A1 (en) 2002-03-08 2003-09-22 Heloise, Anne, Pereira, Ph. D. An early detection marker for chronic inflammatory associated diseases
WO2004016653A2 (en) 2002-08-15 2004-02-26 Leukotech A/S Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) or human neutrophil elastase
RU2005129745A (ru) * 2003-02-24 2006-03-20 Джитиси Байотерапьютикс, Инк. (Us) Способы и устройство проточной фильтрации вдоль потока
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
WO2004112713A2 (en) 2003-06-20 2004-12-29 Royer Biomedical, Inc. Drug polymer complexes
WO2005028512A1 (en) 2003-09-19 2005-03-31 Leukotech A/S Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
JP2008538007A (ja) * 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
CA2624569A1 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
FR2894675B1 (fr) 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
GB0711327D0 (en) 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method

Also Published As

Publication number Publication date
AU2008261252A1 (en) 2008-12-18
PT2129391E (pt) 2012-06-06
SI2129391T1 (sl) 2012-07-31
PL2129391T3 (pl) 2012-09-28
CA2690067C (en) 2023-09-19
ES2380875T3 (es) 2012-05-21
US20140187503A1 (en) 2014-07-03
CN101687023A (zh) 2010-03-31
EP2129391A1 (en) 2009-12-09
BRPI0812875B1 (pt) 2017-12-05
DK2129391T3 (da) 2012-06-11
US8518648B2 (en) 2013-08-27
CN103543271A (zh) 2014-01-29
GB0711327D0 (en) 2007-07-25
AU2008261252B2 (en) 2013-03-14
US9784741B2 (en) 2017-10-10
US20100305185A1 (en) 2010-12-02
KR20100021578A (ko) 2010-02-25
EP2129391B1 (en) 2012-03-07
CA2690067A1 (en) 2008-12-18
KR101563997B1 (ko) 2015-10-28
WO2008151808A1 (en) 2008-12-18
CN101687023B (zh) 2016-04-20
JP2010529468A (ja) 2010-08-26
BRPI0812875B8 (pt) 2022-07-12
ATE548050T1 (de) 2012-03-15
US20130252347A1 (en) 2013-09-26
JP5166522B2 (ja) 2013-03-21

Similar Documents

Publication Publication Date Title
BRPI0812875B8 (pt) " método in vitro para indentificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, e, kit de teste
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
NZ592552A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
BRPI0820885B8 (pt) "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)".
WO2007035633A3 (en) Screening assays and methods
BRPI0906903B8 (pt) anticorpo monoclonal e método de detecção da expressão de cd70
ATE514950T1 (de) Verfahren zur untersuchung von sepsis bei menschen
NZ600828A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ATE485514T1 (de) Immunoassay mit mehreren analyten
NZ619883A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
DE60228557D1 (de) Candida-nachweis
JP2009537798A5 (pt)
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
RU2011125320A (ru) Способы, устройства и наборы для детекции или мониторинга острого повреждения почек
EP1708745A4 (en) ANTIBODIES FOR ONCOGENIC STRAINS OF HPV AND METHOD FOR THEIR USE
ATE464374T1 (de) Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
EP2074427A4 (en) Diagnostic biomolecule(s)
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
WO2007117330A3 (en) Latent protein c assays and their uses for diagnosis and/or prognosis in systemic inflammatory response syndromes
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
DE602006015727D1 (de) Verfahren zur messung von plasmaspiegeln von pentraxin ptx3
ATE427494T1 (de) Verfahren zur quantifizierung der akt-protein- expression
ATE447711T1 (de) System zur internen, qualitativen und quantitativen überprüfung von zellmarker-indices
ATE467128T1 (de) Kolloidale metallkonjugate

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25D Requested change of name of applicant approved